- If approved by the European Commission (EC), VENCLYXTO® plus rituximab would be the first chemotherapy-free combination regimen with a fixed duration of treatment for patients with chronic lymphocytic leukemia who have received at least one prior therapy.
- The positive opinion is based on the MURANO Phase 3 clinical trial, in which VENCLYXTO plus rituximab met the primary endpoint of prolonged progression-free survival and the majority of patients achieved undetectable minimal residual disease in the peripheral blood, compared to a standard of care chemoimmunotherapy regimen of bendamustine plus rituximab.[1]
- The safety profile of the combination of VENCLYXTO plus rituximab is consistent with the known safety profile of each medicine alone.[1]
PR Newswire
NORTH CHICAGO, Ill., Sept. 21, 2018
